The polyphenol Oleuropein aglycone hinders the growth of toxic transthyretin amyloid assemblies

Journal of Nutritional Biochemistry

Volumn 30, Issue , 2016, Pages 153-166

  Leri, Manuela ^a   Nosi, Daniele ^a   Natalello, Antonino ^b   Porcari, Riccardo ^c   Ramazzotti, Matteo ^a   Chiti, Fabrizio ^a,e   Bellotti, Vittorio ^c,d   Doglia, Silvia Maria ^b   Stefani, Massimo ^a,d   Bucciantini, Monica ^a,d  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF PAVIA   (Italy)

^e Centro Interuniversitario per lo Studio delle Malattie Neurodegenerative (CIMN)   (Italy)

Author keywords

Amyloid; FAC; FAP; Oleuropein aglycone; Transthyretin

Indexed keywords

ACRYLAMIDE; AGLYCONE; AMYLOID; EXTRA VIRGIN OLIVE OIL; MOLECULAR SCAFFOLD; OLEUROPEIN; POLYPHENOL; PREALBUMIN; PROTEIN AGGREGATE; IRIDOID;

ANIMAL CELL; ARTICLE; BINDING SITE; CELL CULTURE; CELL MEMBRANE; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; HEART MUSCLE CELL; HYDROPHOBICITY; INFRARED SPECTROSCOPY; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN AGGREGATION; PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE;

ANIMALS; CELL LINE; IRIDOIDS; MICE; PREALBUMIN; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84962103806     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2015.12.009     Document Type: Article

References (68)

1. Blake C.C., Geisow M.J., Swan I.D.A. Structure of human plasma prealbumin at 2-5 a resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. J Mol Biol 1974, 88:1-12.
2. Dickson P.W., Aldred A.R., Marley P.D., Tu G.F., Howlett G.J., Schreiber G. High prealbumin and transferrin mRNA levels in the choroid plexus of rat brain. Biochem Biophys Res Commun 1985, 127:890-895.
3. Noy N., Slosberg E., Scarlata S. Interactions of retinol with binding proteins: studies with retinol-binding protein and with transthyretin. Biochemistry 1992, 31:11118-11124.
4. Sekijima Y., Kelly J.W., Ikeda S. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008, 14:3219-3230.
5. Cornwell III G.G., Murdoch W.L., Kyle R.A., Westermark P., Pitkanen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 1983, 75:618-623.
6. Westermark P., Sletten K., Johansson B., Cornwell III G.G. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 1990, 87:2843-2845.
7. Connors L.H., Lim A., Prokaeva T., Roskens V.A., Costello C.E. Tabulation of human transthyretin (TTR) variants 2003. Amyloid 2003, 10:160-184.
8. Soares M.L., Coelho T., Sousa A., Holmgren G., Saraiva M.J., Kastner D.L., et al. Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden. Eur J Hum Genet 2004, 12:225-237.
9. Keetch C.A., Bromley E.H., McCammon M.G., Wang N., Christodoulou J., Robinson C.V. L55P transthyretin accelerates subunit exchange and leads to rapid formation of hybrid tetramers. J Biol Chem 2005, 280:41667-41674.
10. Reixach N., Deechongkit S., Jiang X., Kelly J.W., Buxbaum J.N. Tissue damage in the amyloidoses: transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A 2004, 101:2817-2822.
11. Hammarstrom P., Wiseman R.L., Powers E.T., Kelly J.W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003, 299:713-716.
12. Obici L., Merlini G. An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opin Investig Drugs 2014, 23:1239-1251.
13. Stefani M., Rigacci S. Beneficial properties of natural phenols: highlight on protection against pathological conditions associated with amyloid aggregation. Biofactors 2014, 40:482-493.
14. Queen B.L., Tollefsbol T.O. Polyphenols and aging. Curr Aging Sci 2010, 3:34-42.
15. Scarmeas N.Y., Stern M.X., Tang R., Mayeux J.A., Luchsinger J.A. Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 2006, 59:912-921.
16. Feart C., Samieri C., Barberger-Gateau P. Mediterranean diet and cognitive function in older adults. Curr Opin Clin Nutr Metab Care 2010, 13:14-18.
17. Rigacci S., Guidotti V., Bucciantini M., Parri M., Nediani C., Cerbai E., et al. Oleuropein aglycon prevents cytotoxic amyloid aggregation of human amylin. J Nutr Biochem 2010, 21:726-735.
18. Rigacci S., Guidotti V., Bucciantini M., Nichino D., Relini A., Berti A., et al. Aβ(1-42) aggregates into non-toxic amyloid assemblies in the presence of the natural polyphenol oleuropein aglycon. Curr Alzheimer Res 2011, 8:841-852.
19. Daccache A., Lion C., Sibille N., Gerard M., Slomianny C., Lippens G., et al. Oleuropein and derivatives from olives as tau aggregation inhibitors. Neurochem Int 2011, 58:700-707.
20. Diomede L., Rigacci S., Romeo M., Stefani M., Salmona M. Oleuropein aglycone protects transgenic C. elegans strains expressing Aβ42 by reducing plaque load and motor deficit. PLoS One 2013, 8.
21. Luccarini I., Grossi C., Rigacci S., Coppi E., Pugliese A.M., Pantano D., et al. Oleuropein aglycone protects against pyroglutamylated-3 amyloid-ß toxicity: biochemical, epigenetic and functional correlates. Neurobiol Aging 2015, 36:648-663.
22. Ladiwala A.R., Dordick J.S., Tessier P.M. Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways. J Biol Chem 2011, 286:3209-3218.
23. Miyata M., Sato T., Kugimiya M., Sho M., Nakamura T., Ikemizu S., et al. The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Biochemistry 2010, 49:6104-6114.
24. Ferreira N., Santos S.A., Domingues M.R., Saraiva M.J., Almeida M.R. Dietary curcumin counteracts extracellular transthyretin deposition: insights on the mechanism of amyloid inhibition. Biochim Biophys Acta 1832, 2013:39-45.
25. Ferreira N., Saraiva M.J., Almeida M.R. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett 2011, 585:2424-2430.
26. White S.M., Constantin P.E., Claycomb W.E. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol 2004, 286:H823-H829.
27. Mangione P.P., Porcari R., Gillmore J.D., Pucci P., Monti M., Porcari M., et al. Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc Natl Acad Sci U S A 2014, 111:1539-1544.
28. Bonifacio M.J., Sakaki Y., Saraiva M.J. "In vitro" amyloid fibril formation from transthyretin: the influence of ions and the amyloidogenicity of TTR variants. Biochim Biophys Acta 1996, 1316:35-42.
29. Nilsson M.R. Techniques to study amyloid fibril formation in vitro. Methods 2004, 34:151-160.
30. Frid P., Anisimov S.V., Popovic N. Congo red and protein aggregation in neurodegenerative diseases. Brain Res Rev 2007, 53:135-160.
31. Sartiani L., Bochet P., Cerbai E., Mugelli A., Fischmeister R. Functional expression of the hyperpolarization-activated, non-selective cation current I(f) in immortalized HL-1 cardiomyocytes. J Physiol 2002, 545:81-92.
32. Nosi D., Mercatelli R., Chellini F., Soria S., Pini A., Formigli L., et al. A molecular imaging analysis of Cx43 association with Cdo during skeletal myoblast differentiation. J Biophotonics 2012, 6:612-661.
33. Natalello A., Ami D., Doglia S.M. Fourier transform infrared spectroscopy of intrinsically disordered proteins: measurement procedures and data analyses. Methods Mol Biol 2012, 895:229-244.
34. Ami D., Ricagno S., Bolognesi M., Bellotti V., Doglia S.M., Natalello A. Structure, stability, and aggregation of β-2 microglobulin mutants: insights from a Fourier transform infrared study in solution and in the crystalline state. Biophys J 2012, 102:1676-1684.
35. Susi H., Byler D.M. Resolution-enhanced Fourier transform infrared spectroscopy of enzymes. Methods Enzymol 1986, 130:290-311.
36. Kumar V., Sharma V.K., Kalonia D.S. Second derivative tryptophan fluorescence spectroscopy as a tool to characterize partially unfolded intermediates of proteins. Int J Pharm 2005, 294:193-199.
37. Souillac P.O., Uversky V.N., Fink A.L. Structural transformations of oligomeric intermediates in the fibrillation of the immunoglobulin light chain LEN. Biochemistry 2003, 42:8094-8104.
38. Pitozzi V., Jacomelli M., Zaid M., Luceri C., Bigagli E., Lodovici M., et al. Effects of dietary extra-virgin olive oil on behaviour and brain biochemical parameters in ageing rats. Br J Nutr 2010, 11:1674-1683.
39. Farr S.A., Price TO, Dominguez L.J., Motisi A., Saiano F., Niehoff M.L., et al. Extra virgin olive oil improves learning and memory in SAMP8 mice. J Alzheimers Dis 2012, 28:81-92.
40. Shen Y., Song S.J., Keum N., Park T. Olive leaf extract attenuates obesity in high-fat diet-fed mice by modulating the expression of molecules involved in adipogenesis and thermogenesis. Evid Based Complement Altern Med 2012, 2014:971890.
41. Omar S.H. Cardioprotective and neuroprotective roles of oleuropein in olive. Saudi Pharm J 2010, 18:111-121.
42. Lai Z., Colón W., Kelly J.W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996, 35:6470-6482.
43. Pires R.H., Karsai Á., Saraiva M.J., Damas A.M., Kellermayer M.S. Distinct annular oligomers captured along the assembly and disassembly pathways of TransthyretinAmyloid protofibrils. PLoS One 2012, 7.
44. Cordeiro Y., Kraineva J., Suarez M.C., Tempesta A.G., Kelly J.W., Silva J.L., et al. Fourier transform infrared spectroscopy provides a fingerprint for the tetramer and for the aggregates of transthyretin. Biophys J 2006, 91:957-967.
45. Zandomeneghi G., Krebs M.R., McCammon M.G., Fändrich M. FT-IR reveals structural differences between native beta-sheet proteins and amyloid fibrils. Protein Sci 2004, 13:3314-3321.
46. Tallmadge D.H., Huebner J.S., Borkman R.F. Acrylamide quenching of tryptophan photochemistry and photophysics. Photochem Photobiol 1989, 49:381-386.
47. Mannini B., Mulvihill E., Sgromo C., Cascella R., Khodarahmi R., Ramazzotti M., et al. Toxicity of protein oligomers is rationalized by a function combining size and surface hydrophobicity. ACS Chem Biol 2014, 9:2309-2317.
48. Grossi C., Rigacci S., Ambrosini S., Ed Dami T., Luccarini I., Traini C., et al. The polyphenol oleuropein aglycone protects TgCRND8 mice against Aß plaque pathology. PLoS One 2013, 8.
49. Bucciantini M., Nosi D., Forzan M., Russo E., Calamai M., Pieri L., et al. Toxic effects of amyloid fibrils on cell membranes: the importance of ganglioside GM1. FASEB J 2012, 262:818-831.
50. Matsuzaki K. How do membranes initiate Alzheimer's disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters. Acc Chem Res 2014, 478:2397-2404.
51. Bastianetto S., Quirion R. Natural antioxidants and neurodegenerative diseases. Front Biosci 2004, 9:3447-3452.
52. Pawar A.P., Dubay K.F., Zurdo J., Chiti F., Vendruscolo M., Dobson C.M. Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. J Mol Biol 2005, 350:379-392.
53. Bourgault S., Choi S., Buxbaum J.N., Kelly J.W., Price J.L., Reixach N. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun 2011, 410:707-713.
54. Kristen A.V., Lehrke S., Buss S., Mereles D., Steen H., Ehlermann P., et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 2012, 101:805-813.
55. Aus Dem Siepen F., SJ Buss, Andre F., Seitz S., Giannitsis E., Steen H., et al. Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clin Res Cardiol 2015, 104:640-647.
56. Andreadou I., Mikros E., Ioannidis K., Sigala F., Naka K., Kostidis S., et al. Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. J Mol Cell Cardiol 2014, 69:4-16.
57. Yang M., Lei M., Huo S. Why is Leu55 → Pro55 transthyretin variant the mostamyloidogenic: insights from molecular dynamics simulations of transthyretin monomers. Protein Sci 2003, 12:1222-1231.
58. Porat Y., Mazor Y., Efrat S., Gazit E. Inhibition of islet amyloid polypeptide fibril formation: a potential role for heteroaromatic interactions. Biochemistry 2004, 43:14454-14462.
59. Wu C., Lei H., Wang Z., Zhang W., Duan Y. Phenol red interacts with the protofibril-like oligomers of an amyloidogenic hexapeptide NFGAIL through both hydrophobic and aromatic contacts. Biophys J 2006, 91:3664-3672.
60. Gazit E. A possible role for π-stacking in self-assembly of amyloid fibrils. FASEB J 2002, 16:77-83.
61. Porat Y., Abramowitz A., Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006, 67:27-37.
62. Tipping K.W., Karamanos T.K., Jakhria T., Iadanza M.G., Goodchild S.C., Tuma R., et al. pH-induced molecular shedding drives the formation of amyloid fibril-derived oligomers. PNAS 2015, 112:5691-5696.
63. Westermark G., Westermark P. Transthyretin and amyloid in the islets of Langerhans in type-2 diabetes. Exp Diabetes Res 2008, 2008:429274.
64. Eisele Y.S., Monteiro C., Fearns C., Encalada S.E., Wiseman R.L., Powers E.T., et al. Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov 2015, 14:759-780.
65. Hou X., Richardson S.J., Aguilar M.I., Small D.H. Binding of amyloidogenic transthyretin to the plasma membrane alters membrane fluidity and induces neurotoxicity. Biochemistry 2005, 44:11618-11627.
66. Pieri L., Madiona K., Bousset L., Melki R. Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys J 2012, 102:2894-2905.
67. Hong S., Ostaszewski B.L., Yang T., O'Malley T.T., Jin M., Yanagisawa K., et al. Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron 2014, 82:308-319.
68. Hou X., Mechler A., Martin L.L., Aguilar M.I., Small D.H. Cholesterol and anionic phospholipids increase the binding of amyloidogenic transthyretin to lipid membranes. Biochim Biophys Acta 1778, 2008:198-205.